Praluent (Alirocumab) Drug Interactions: 1 Moderate
Praluent (Alirocumab) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Praluent. Always confirm against the full prescribing information.
100 interactions
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Alirocumab.
Level 2 evidence
Aducanumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Aducanumab.
Level 2 evidence
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Alirocumab.
Level 2 evidence
Amivantamab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Amivantamab.
Level 2 evidence
Anifrolumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Anifrolumab.
Level 2 evidence
Ansuvimab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Ansuvimab.
Level 2 evidence
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Alirocumab.
Level 2 evidence
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Alirocumab is combined with Antilymphocyte immunoglobulin (horse).
Level 2 evidence
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Alirocumab.
Level 2 evidence
Asfotase alfa
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Alirocumab.
Level 2 evidence
Atezolizumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Atezolizumab.
Level 2 evidence
Atoltivimab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Atoltivimab.
Praluent (Alirocumab) has 163 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Praluent (Alirocumab) has 0 major, 1 moderate, and 162 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Praluent. Always confirm against the full prescribing information.